A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia

Bhanji, Nadeem H.; Chouinard, Guy; Margolese, Howard C.

doi:10.1016/s0924-977x(03)00109-3

Cited by 87 publications

(53 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…LAI preparations offer important options for treatment of chronic diseases and are particularly important for enhancing adherence, which may in turn benefit treatment outcomes and quality of life (Bhanji et al, 2004;Love, 2002;Marinis et al, 2007;Nasrallah et al, 2004). Adherence to treatment is probably a major reason for the lower risk for relapse with LAI formulations vs oral antipsychotic therapy.…”

Section: Discussionmentioning

confidence: 99%

A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia

Nasrallah

Gopal

Gassmann-Mayer

et al. 2010

Neuropsychopharmacol

135

View full text Add to dashboard Cite

Paliperidone palmitate is a long-acting injectable antipsychotic agent. This 13-week, multicenter, randomized (1 : 1 : 1 : 1), double-blind, parallel-group study evaluated the efficacy, safety, and tolerability of fixed 25, 50, and 100 milligram equivalent (mg equiv.) doses of paliperidone palmitate vs placebo administered as gluteal injections on days 1 and 8, then every 4 weeks (days 36 and 64) in 518 adult patients with schizophrenia. The intent-to-treat analysis set (N ¼ 514) was 67% men and 67% White, with a mean age of 41 years. All paliperidone palmitate dose groups showed significant improvement vs placebo in the Positive and Negative Syndrome Scale (PANSS) total score (primary efficacy measure; 25 and 50 mg equiv., p ¼ 0.02; 100 mg equiv., po0.001), as well as Clinical Global Impression Severity scores (pp0.006) and PANSS negative and positive symptom Marder factor scores (pp0.04). The Personal and Social Performance scale showed no significant difference between treatment groups. The overall incidence of treatment-emergent adverse events was similar between groups. Parkinsonism, the most frequently reported extrapyramidal symptom, was reported at similar rates for placebo (5%) and paliperidone palmitate (5-6% across doses). The mean body mass index and mean weight showed relatively small dose-related increases during paliperidone palmitate treatment. Investigator-evaluated injection-site pain, swelling, redness, and induration were similar across treatment groups; scores for patient-evaluated injection-site pain (visual analog scale) were similar across groups and diminished with time. All doses of once-monthly paliperidone palmitate were efficacious and generally tolerated, both locally and systemically. Paliperidone palmitate offers the potential to improve outcomes in adults with symptomatic schizophrenia.

show abstract

Section: Discussionmentioning

confidence: 99%

A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia

Nasrallah

Gopal

Gassmann-Mayer

et al. 2010

Neuropsychopharmacol

135

View full text Add to dashboard Cite

show abstract

“…Although many IM-injected drugs are delivered in an aqueous vehicle, oil vehicle IM injections are confined to the delivery of sex steroids [2] or neuroleptic drugs [3,4] as depot formulations. These involve the administration of pro-drug esters with the active drug released by side chain hydrolysis, a cleavage produced by ubiquitous nonspecific esterases.…”

Section: Introductionmentioning

confidence: 99%

Factors influencing time course of pain after depot oil intramuscular injection of testosterone undecanoate

Sartorius¹,

Fennell²,

Spasevska³

et al. 2010

Asian J Androl

View full text Add to dashboard Cite

Pain following depot intramuscular (IM) injection of oil vehicle-based drugs has been little studied. This study aimed to determine prospectively the prevalence, determinants, severity and functional consequences of pain during the week after IM injection of 1 000 mg testosterone undecanoate (TU) in a 4-mL castor oil vehicle. Androgendeficient men receiving regular T replacement therapy at an academic andrology clinic were recruited to report pain scores using a coloured visual linear analogue scale at seven times over the first day and daily for a week after a deep IM gluteal injection. The time course and covariables influencing pain scores were analysed by mixed model analysis of variance (ANOVA). Following 168 injections in 125 men, pain was reported by 80% of men, peaking immediately after injection, reaching only moderate severity, lasting 1-2 days and returning to baseline by day 4. The pain required little analgesic use and produced minimal interference in daily activities. The time course of pain scores was reproducible in the 43 men who underwent two consecutive injections. Pain was more severe in men who had an earlier painful injection, but less severe in older and more obese men. There were negligible differences in post-injection pain experience between experienced nurses administering injections. Deep IM gluteal injection of depot TU in 4-mL castor oil is well tolerated and post-injection pain is influenced by earlier painful injection experience, as well as age and obesity.

show abstract

“…These preparations ensure the administration of medications and decrease variations in drug serum level, thereby increasing efficacy and tolerance of the drugs (Davis et al, 1994;Kane et al, 1998). However, typical depot antipsychotic medications still have the most significant complication of typical antipsychotic neuroleptic therapy, the development of extrapyramidal symptoms (Bhanji et al, 2004). Therefore, long-acting formulations of atypical antipsychotic medications with more positive safety profiles are needed.…”

Section: Introductionmentioning

confidence: 99%

Long‐term treatment with long‐acting risperidone in Korean patients with schizophrenia

Lee

et al. 2006

Human Psychopharmacology

View full text Add to dashboard Cite

show abstract

A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia

Cited by 87 publications

References 31 publications

A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia

A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia

Factors influencing time course of pain after depot oil intramuscular injection of testosterone undecanoate

Long‐term treatment with long‐acting risperidone in Korean patients with schizophrenia

Contact Info

Product

Resources

About